ArticleNature2019
KRAS4A directly regulates hexokinase 1.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 148 papers.
0numbers the graph read from it
0cells of the map it votes in
148citing papers in PubMed
6.1field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
148 citing papers in PubMed, 199 citations in OpenAlex.
- Photocatalytic proximity labeling for the identification of G-quadruplex DNA-interacting proteins.Communications chemistry · 2026Article
- The Metabolic Rheostat Index Uncovers Pathway-Level Coordination, Immunosuppressive Microenvironment Remodeling, and Therapeutic Co-Vulnerabilities in Pancreatic Ductal Adenocarcinoma.Current issues in molecular biology · 2026Article
- KRAS signaling networks, mutational heterogeneity, and emerging therapeutic strategies for cancer treatment.Biomarker research · 2026Review
- Alternative Splicing in Cyclin-Dependent Kinase 4/6 Inhibitor Resistance in Estrogen Receptor-Positive Breast Cancer.Drug development research · 2026Review
- Bioengineered systems to exploit tumor microenvironment metabolism.Trends in cancer · 2026Review
- Hypoxia-induced metastatic heterogeneity in pancreatic cancer.Nature communications · 2026Article
- Revisiting RAS family GTPase signaling: effector selectivity and oncogenic bypass.The Biochemical journal · 2026Review
- Tumor cell death by ferroptosis contributes to an immunosuppressive tumor microenvironment in syngeneic murine models of cancer.Cancer & metabolism · 2026Article
- Palmitoylation remodeling dictates HCC heterogeneity: implications for subtype-specific prognostication and targeting the YAP-RhoA axis.BMC medical genomics · 2026Article
- De novo design of Ras isoform selective binders.Cell chemical biology · 2026Article
- Systematic and precise interventions for KRAS-mutant cancers.Experimental hematology & oncology · 2026Review
- Metabolic permissiveness: how tissue context shapes cancer.Genes & development · 2026Review
- USP30-mediated Deubiquitination of Hexokinase 2 controls the metabolic fate of glucose and tumor progression.Cell death & disease · 2026Article
- The moonlighting functions of glycolytic enzymes in tumorigenesis.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- A Cori cycle-related gene signature predicts prognosis, immune microenvironment, and drug response in breast cancer.Translational cancer research · 2026Article
- Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations.Signal transduction and targeted therapy · 2026Article
- Tumor cell death by ferroptosis contributes to an immunosuppressive tumor microenvironment in syngeneic murine models of cancer.bioRxiv : the preprint server for biology · 2026Article
- S-palmitoylation in ferroptosis: molecular mechanisms, modulators, and interplay with autophagy.Apoptosis : an international journal on programmed cell death · 2026Review
- Bridging metabolic reprogramming and targeted therapy: the critical role of S-palmitoylation in cancer.Frontiers in cell and developmental biology · 2026Review
- Unravelling Resistance: Integrating Metabolism, Epigenetics, Immunology, and Proteostasis in Strategies against Kirsten Rat Sarcoma Viral Oncogene Homolog-mutant Colorectal Cancer.International journal of biological sciences · 2026Review
88 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 2 countries.
Caroline R AmendolaPerlmutter Cancer Center, NYU School of Medicine, New York, NY, USA.
James P MahaffeyPerlmutter Cancer Center, NYU School of Medicine, New York, NY, USA.
Seth J ParkerPerlmutter Cancer Center, NYU School of Medicine, New York, NY, USA.
Ian M AhearnPerlmutter Cancer Center, NYU School of Medicine, New York, NY, USA.
Wei-Ching ChenHelen Diller Family Comprehensive Cancer Center, University of California at San Francisco School of Medicine, San Francisco, CA, USA.
Mo ZhouPerlmutter Cancer Center, NYU School of Medicine, New York, NY, USA.
Helen CourtPerlmutter Cancer Center, NYU School of Medicine, New York, NY, USA.
Jie ShiPerlmutter Cancer Center, NYU School of Medicine, New York, NY, USA.
Sebastian L MendozaPerlmutter Cancer Center, NYU School of Medicine, New York, NY, USA.
Michael J MortenPerlmutter Cancer Center, NYU School of Medicine, New York, NY, USA.
Eli RothenbergPerlmutter Cancer Center, NYU School of Medicine, New York, NY, USA.
Eyal GottliebTechnion Israel Institute of Technology, Haifa, Israel.
Youssef Z WadghiriPerlmutter Cancer Center, NYU School of Medicine, New York, NY, USA.
Richard PossematoPerlmutter Cancer Center, NYU School of Medicine, New York, NY, USA.
Stevan R HubbardPerlmutter Cancer Center, NYU School of Medicine, New York, NY, USA.
Allan BalmainHelen Diller Family Comprehensive Cancer Center, University of California at San Francisco School of Medicine, San Francisco, CA, USA.
Alec C KimmelmanPerlmutter Cancer Center, NYU School of Medicine, New York, NY, USA.
Mark R PhilipsPerlmutter Cancer Center, NYU School of Medicine, New York, NY, USA. mark.philips@nyulangone.org.
NYU Langone’s Laura and Isaac Perlmutter Cancer CenterUCSF Helen Diller Family Comprehensive Cancer Center · USTechnion – Israel Institute of Technology · IL
Funding
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ADRIANA HEGUY · 1985 to 2026
$83.1MThe RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2006 to 2025
$41.7MTR&D 4: Revealing Microstructure: Biophysical modeling and validation for discovery and clinical careP41EB017183 · NIBIB · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Hersh Chandarana · 2014 to 2026
$19.3MTRAINING PROGRAM IN MOLECULAR ONCOLOGY &IMMUNOLOGYT32CA009161 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARROLL, WILLIAM L., LEVY, DAVID E · 1985 to 2020
$13.3MSystems genetics analysis of tumor evolution in the mouseR35CA210018 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALLAN BALMAIN · 2017 to 2026
$8.0MIdentifying Metabolic Dependencies of Pancreatic CancersR35CA232124 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KIMMELMAN, ALEC · 2018 to 2024
$6.5MIntegrating targeted and immunotherapy to treat genetically heterogeneous cancersU01CA217864 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BALMAIN, ALLAN, KRUMMEL, MATTHEW F · 2017 to 2021
$5.1MRegulation of K-Ras by a Farnesyl-electrostatic SwitchR01CA116034 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PHILIPS, MARK REID · 2005 to 2017
$3.4MNetwork organization of the human autophagy systemR01GM095567 · NIGMS · HARVARD MEDICAL SCHOOL · PI HARPER, JEFFREY W, KIMMELMAN, ALEC · 2011 to 2018
$3.0MIsoprenylcysteine Carboxyl Methyltransferase (ICMT) as a Target in NRAS Driven Melanoma - Resubmission - 1R01CA163489 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PHILIPS, MARK REID · 2012 to 2020
$2.8MInvestigating the Role of Autophagy in Pancreatic Cancer Radiation ResistanceR01CA157490 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KIMMELMAN, ALEC · 2011 to 2018
$2.5MTargeting Metabolic Liabilities in CancerR01CA214948 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI POSSEMATO, RICHARD LEWIS · 2018 to 2022
$1.9MNCI NIH HHS P01 CA117969NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA116034NCI NIH HHS R01 CA157490NCI NIH HHS R01 CA163489NCI NIH HHS R01 CA188048NCI NIH HHS R01 CA214948NCI NIH HHS R35 CA210018NCI NIH HHS R35 CA232124NCI NIH HHS T32 CA009161NCI NIH HHS U01 CA217864NIBIB NIH HHS P41 EB017183NIGMS NIH HHS R01 GM095567NIGMS NIH HHS T32 GM088118
Abstract
The most frequently mutated oncogene in cancer is KRAS, which uses alternative fourth exons to generate two gene products (KRAS4A and KRAS4B) that differ only in their C-terminal membrane-targeting region
Indexed as
Allosteric RegulationAnimalsCell Line, TumorEnzyme ActivationGlycolysisGuanosine TriphosphateHexokinaseHumansIn Vitro TechniquesIsoenzymesLipoylationMaleMiceMitochondriaMitochondrial MembranesNeoplasmsGuanosine TriphosphateHexokinaseHK1 protein, humanIsoenzymesKRAS protein, humanProto-Oncogene Proteins p21(ras)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.